Cancer Biotech Lands $145M for First-in-Class Drug to Block Elusive Tumor Target

FogPharma, a biotech company based in Cambridge, Massachusetts, has secured $145 million in funding for the clinical development of their novel therapeutic candidate for solid tumors. The drug, FOG-001, targets the Wnt/beta-catenin signaling pathway, which is linked to various types of cancer. The company’s unique peptide drugs, called Helicon therapeutics, are designed to penetrate cells and modulate protein interactions. FogPharma’s pipeline includes programs targeting prostate cancer, ovarian cancer, lung cancer, and more. The recent Series E financing round was led by Nextech Invest, with other investors including RA Capital Management and Johnson & Johnson’s former chairman Alex Gorsky.

Source link

error: Content is protected !!